Everything below concerns pentapeptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-07-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.
Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.
Human data remain limited and come mainly from small, short-term studies conducted decades ago. The peptide has not received approval as a medicine from major regulators, so current availability is largely as a research chemical. Reported effects on growth hormone pulsatility, appetite, and body composition should be read as preliminary, since few independent groups have replicated the original findings. Analytical characterization of research-grade material varies between suppliers, which complicates comparison across studies. Regulatory status also differs by country, and some jurisdictions classify it as a prescription-only or otherwise restricted item.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentapeptide | Growth hormone secretagogue family |
| Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 | Contains two non-natural residues |
| Molecular formula | C38H49N9O5 | Free base form |
| Molecular weight | 711.85 g/mol | Calculated from formula |
| Primary target | GHS-R1a ghrelin receptor | Agonist activity |
Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.
从用途定位看，ipamorelin 目前主要以研究用肽的身份被讨论，未见主要药品监管机构将其批准为治疗药物。市售材料通常标注仅供研究使用，不得用于人体或诊断程序。文献中它常与生长激素促分泌素、GHS-R1a 激动剂、胃饥饿素拟似物等表述并列出现。既有研究的样本量普遍偏小，因此对其效应强度与一致性的描述应保持谨慎。
Ipamorelin 是一种合成五肽，序列为 Aib-His-D-2-Nal-D-Phe-Lys-NH2，分子式 C38H49N9O5，游离碱分子量约 711.85 g/mol。它属于生长激素促分泌素（GHS）家族，作用靶点是胃饥饿素受体 GHS-R1a。该化合物由诺和诺德的研究团队在二十世纪九十年代末报道，设计目标是提高对生长激素释放的选择性。C 端酰胺化与 N 端 Aib 残基是两个用于抵抗肽酶降解的结构特征。
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Interest in a possible island of stability grew throughout the 1960s, as some calculations suggested that it might contain nuclides with half-lives of billions of years. They were also predicted to be especially stable against spontaneous fission in spite of their high atomic mass. It was thought that if such elements exist and are sufficiently long-lived, there may be several novel applications as a consequence of their nuclear and chemical properties. These include use in particle accelerators as neutron sources, in nuclear weapons as a consequence of their predicted low critical masses and high number of neutrons emitted per fission, and as nuclear fuel to power space missions. These speculations led many researchers to conduct searches for superheavy elements in the 1960s and 1970s, both in nature and through nucleosynthesis in particle accelerators. During the 1970s, many searches for long-lived superheavy nuclei were conducted. Experiments aimed at synthesizing elements ranging in atomic number from 110 to 127 were conducted at laboratories around the world. These elements were sought in fusion-evaporation reactions, in which a heavy target made of one nuclide is irradiated by accelerated ions of another in a cyclotron, and new nuclides are produced after these nuclei fuse and the resulting excited system releases energy by evaporating several particles (usually protons, neutrons, or alpha particles).
This sheath could also play an important role in reducing the damage to Osedax skin by absorbing harmful acid. Another potential function of the mucus sheath is that it could inhibit the breakdown of the worm's bone matrix. This is significant because the bone matrix is integral in maintaining the worm's position while in direct contact with a bone.
== See also == André Michaux, introduced the ginkgo to North America Bartheletia paradoxa, a unique species of fungus that grows exclusively on Ginkgo leaves Ginkgo Petrified Forest State Park in central Washington, United States Herbalism List of edible seeds
In 2000, John Pendry was the first to identify a practical way to make a left-handed metamaterial, a material in which the right-hand rule is not followed. Such a material allows an electromagnetic wave to convey energy (have a group velocity) against its phase velocity. Pendry hypothesized that metallic wires aligned along the direction of a wave could provide negative permittivity (dielectric function ε < 0). Natural materials (such as ferroelectrics) display negative permittivity; the challenge was achieving negative permeability (μ < 0). In 1999, Pendry demonstrated that a split ring (C shape) with its axis placed along the direction of wave propagation could do so. In the same paper, he showed that a periodic array of wires and rings could give rise to a negative refractive index. Pendry also proposed a related negative-permeability design, the Swiss roll. In 2000, David R. Smith et al. reported the experimental demonstration of functioning electromagnetic metamaterials by horizontally stacking, periodically, split-ring resonators and thin wire structures. A method was provided in 2002 to realize negative-index metamaterials using artificial lumped-element loaded transmission lines in microstrip technology. In 2003, complex (both real and imaginary parts of) negative refractive index and imaging by flat lens using left handed metamaterials were demonstrated. Negative index of refraction in the optical range was first demonstrated by Vladimir Shalaev et al. By 2007, experiments that involved negative refractive index had been conducted by many groups.
Sources: en.wikipedia.org
Most of the run-through schemes are in stand-alone specialties (e.g., radiology, public health, histopathology), but there are also a few traditionally surgical specialities which can be entered directly without completing core surgical training (e.g., neurosurgery, obstetrics & gynaecology, ophthalmology). The length of this training varies; for example, general practice is three years while radiology is five years. The UK grade equivalent of a US fellow in medical/surgical sub-specialties is the specialty registrar (ST3–ST9) grade of sub-specialty training. However, while US fellowship programmes are generally 2–3 years in duration after completing the residency, UK trainees spend 4–7 years. This generally includes service provision in the main specialty; this discrepancy lies in the competing demands of NHS service provision, and UK postgraduate training stipulating that even specialist registrars must be able to accommodate the general acute medical take—almost equivalent to what dedicated attending internists perform in the United States (they still remain minimally supervised for these duties). In 2024, the British Medical Association (BMA) advocated for all junior doctors to be renamed residents to prevent the confusion between resident doctors and medical students that terms such as "junior doctors" and "doctors in training" produce.
== Safety == A review of the literature regarding hypnotics including the nonbenzodiazepine Z-drugs concluded that these drugs carry a significant risk to the individual. The risks include dependence, accidents, and other adverse effects. Gradual discontinuation of hypnotics may lead to improved health without worsening of sleep. It is preferred that they should be prescribed for only a few days at the lowest effective dose and avoided wherever possible in the elderly.
=== Parkinson's disease === In its oral and ODT forms, selegiline is used to treat symptoms of Parkinson's disease (PD). It is most often used as an adjunct to medications such as levodopa (L-DOPA), although it has been used off-label as a monotherapy. The rationale for adding selegiline to levodopa is to decrease the required dose of levodopa and thus reduce the motor complications of levodopa therapy. Selegiline delays the point when levodopa treatment becomes necessary from about 11 months to about 18 months after diagnosis. There is some evidence that selegiline acts as a neuroprotective and reduces the rate of disease progression, though this is disputed. In addition to parkinsonism, selegiline can improve symptoms of depression in people with Parkinson's disease. There is evidence that selegiline may be more effective than rasagiline in the treatment of Parkinson's disease. This may be due to pharmacological differences between the drugs, such as the catecholaminergic activity enhancer (CAE) actions of selegiline which rasagiline lacks.
=== Substrate specificity === Octopine dehydrogenase has at least two structural characteristics that contribute to substrate specificity. Upon binding to NADH, amino acid residues lining either side of the active site within the space between the domains of OcDH act as a "molecular ruler", physically limiting the size of the substrates that can fit into the active site. There is also a negatively charged pocket in the cleft between the two domains that acts an "electrostatic sink" that captures the positively charged side-chain of L-arginine.
The modern era or the modern period is considered the current historical period of human history. It was originally applied to the history of Europe and Western history for events that came after the classical antiquity and the Middle Ages, often from around the year 1500, like the Reformation's giving rise to Protestantism in Germany and elsewhere. Since the 1990s, it has been more common among historians to refer to the period after the Middle Ages and up to the 19th century as the early modern period. The modern period is today more often used for events from the 19th century until today. The time from the end of World War II (1945) can also be described as being part of contemporary history. The common definition of the modern period today is often associated with events like the French Revolution, the Industrial Revolution, and the transition from nationalism toward the liberal international order. The modern period has been a period of significant development in the fields of science, politics, warfare, and technology. It has also been an Age of Discovery and globalization. During this time, the European powers and later their colonies, strengthened their political, economic, and cultural colonization of the rest of the world. It also created a new modern lifestyle and has permanently changed the way people around the world live.
Sources: en.wikipedia.org
In Quercus ilex oaks, the fungus neutralizes harmful compounds from the tree's own leaf litter and transfer the nutrients back to the tree through the roots - an essential step for making certain growing conditions possible for these oaks. Another study shows that P.arhizus aided White Cover (Trifolium repens) growth in contaminated mining soils, and improved the growth as well as the mercury tolerance in these flowers by substantial amounts.
where NA0 is the initial number of nuclide A. When measuring the production of one nuclide, one can only observe the total decay constant λ. The decay constants λB and λC determine the probability for the decay to result in products B or C as follows:
where Vp and Q are the volume of the permeate and its volumetric flow rate respectively (proportional to same characteristics of the feed flow), μ is dynamic viscosity of permeating fluid, A is membrane area, Rm and R are the respective resistances of membrane and growing deposit of the foulants. Rm can be interpreted as a membrane resistance to the solvent (water) permeation. This resistance is a membrane intrinsic property and is expected to be fairly constant and independent of the driving force, Δp. R is related to the type of membrane foulant, its concentration in the filtering solution, and the nature of foulant-membrane interactions. Darcy's law allows for calculation of the membrane area for a targeted separation at given conditions. The solute sieving coefficient is defined by the equation:
Board of directors. Jo Coburn (born 12 November 1967); broadcaster and journalist with BBC News, married to former Downing Street head of strategic communications Mark Flanagan; regular presenter of Politics Live (and formerly also Sunday Politics along with Andrew Neil) and previously had special responsibility for BBC Breakfast; former BBC political correspondent for London, who covered the 2000 London Mayoral election; occasional relief presenter on the BBC News Channel. She has presented on BBC Radio 4 in the past and also has guested on the weekend current affairs programme The World This Weekend as well as reviewing the Sunday newspapers on The Andrew Marr Show. Benjamin Cohen (journalist) (born 14 August 1982), web developer, entrepreneur and online publisher; founder of LGBT news site PinkNews;from 2006 until 2012 was technology correspondent for Channel 4 News. He is the Chief Executive of PinkNews, and regularly writes for the London Evening Standard. Dave Cohen (writer); writer for television and radio as well as contributing columns to NME, Chortle and The Huffington Post.; has written for BBC Radio 4 including The Best of British, Dead Ringers which won a Sony Gold Award 2001, The Sunday Format, The News Quiz and 15 Minute Musical which he was also a co-creator and won the 2009 Writer's Guild Best Radio Comedy Show, to name a few. He also wrote for BBC Radio 5's The Treatment and They Came From Nowhere; has written for Rory Bremner Show, Spitting Image, Eleven O'Clock Show, Not Going Out and My Family.
=== Arjo === Arjo was founded in 1957 by Arne Johansson in the Swedish town of Eslöv. The company name consists of the first two letters of the first and last name of the company founder. Arjo initially functioned as a supplier of components and machine parts to medical device manufacturers. In 1972, the company developed the first height-adjustable bathtub and introduced it to the market. In 1993, the company's shares are listed on the Stockholm Stock Exchange and the London Stock Exchange. In 1995, the company merged with the Swedish Getinge Group, in whose "Extended Care" business area it continued to operate under its brand name. In 2004, Arjo took over the company BHM Medical and rounded off its range of passenger lifts with its Ceiling Lifts.
Sources: en.wikipedia.org
It is a synthetic pentapeptide in the growth hormone secretagogue family. The chain contains five residues, two of which are non-natural amino acids.
It acts as an agonist at the growth hormone secretagogue receptor, also known as the ghrelin receptor. Binding at pituitary somatotroph cells promotes growth hormone release.
Early studies report weaker effects on cortisol, prolactin, and appetite than compounds such as GHRP-6. The size of that difference in humans is not firmly established.
It has not been approved as a therapeutic by major regulators, and the human trial record is small and dated. Material available today is mostly sold as a research chemical for laboratory use. Approval and restriction status varies by country.